A preclinical study describes CAR-T cells engineered with a synthetic radiation-inducible promoter that releases TNF locally after tumor irradiation. The approach aims to concentrate inflammatory cytokine effects at the target site, improving antitumor activity while limiting systemic exposure. By coupling an external control signal—radiation—to a localized effector output, the platform targets one of the recurring challenges in cytokine-based enhancement strategies: achieving potency without unacceptable toxicity. While results are limited to preclinical models in the report, the concept may inform next-generation “conditionally activated” cellular therapies that respond to multimodal treatment settings.